Stanniocalcin-1 Reduced Intraocular Pressure in Two Models of Ocular Hypertension

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–67.
   PubMed Web of Science ®Google Scholar
• Linden C, Heijl A, Johannesson G, Aspberg J, Andersson Geimer S, Bengtsson B. Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the glaucoma intensive treatment study. Acta Ophthalmol. 2018;96:567–72.
   PubMed Web of Science ®Google Scholar
• Doucette LP, Walter MA. Prostaglandins in the eye: function, expression, and roles in glaucoma. Ophthalmic Genet. 2017;38:108–16.
   PubMed Web of Science ®Google Scholar
• King A, Azuara-Blanco A, Tuulonen A. Glaucoma. BMJ. 2013;346(f3518).
   Google Scholar
• Tanna AP, Lin AB. Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr Opin Ophthalmol. 2015;26(116–120).
   PubMed Web of Science ®Google Scholar
• Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30:102–09.
   PubMed Web of Science ®Google Scholar
• Cui XJ, Zhao AG, Wang XL. Correlations of afap1, gmds and ptgfr gene polymorphisms with intra-ocular pressure response to latanoprost in patients with primary open-angle glaucoma. J Clin Pharm Ther. 2017;42:87–92.
   PubMed Web of Science ®Google Scholar
• Zhang P, Jiang B, Xie L, Huang W. Ptgfr and slco2a1 gene polymorphisms determine intraocular pressure response to latanoprost in han chinese patients with glaucoma. Curr Eye Res. 2016;41:1561–65.
   PubMed Web of Science ®Google Scholar
• Ussa F, Fernandez I, Brion M, Carracedo A, Blazquez F, Garcia MT, Sanchez-Jara A, De Juan-Marcos L, Jimenez-Carmona S, Juberias JR, et al. Association between snps of metalloproteinases and prostaglandin f2alpha receptor genes and latanoprost response in open-angle glaucoma. Ophthalmology. 2015;122(5):1040–1048 e1044.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Higashide T, Ohkubo S, Takeda H, Sugiyama K. Association between genetic polymorphisms of the prostaglandin f2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. Br J Ophthalmol. 2014;98:469–73.
   PubMed Web of Science ®Google Scholar
• Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin f2alpha receptor gene and response to latanoprost. Ophthalmology. 2007;114:1039–45.
   PubMed Web of Science ®Google Scholar
• Peng HB, Zahary MN, Tajudin LS, Lin CL, Teck CM, Sidek MR, Zulkifli A, Zilfalil BA. A novel single nucleotide polymorphism, ivs2-97a>t, in the prostaglandin f2alpha receptor gene was identified among the malaysian patients with glaucoma. Kobe J Med Sci. 2007;53:49–52.
   PubMedGoogle Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53:S107–120.
   PubMed Web of Science ®Google Scholar
• Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668–72.
   PubMedGoogle Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263–68.
   PubMed Web of Science ®Google Scholar
• Razeghinejad MR. The effect of latanaprost on intraocular inflammation and macular edema. Ocul Immunol Inflamm. 2019;27(2):181–8.
   Web of Science ®Google Scholar
• Roddy GW, Viker KB, Winkler NS, Bahler CK, Holman BH, Sheikh-Hamad D, Roy Chowdhury U, Stamer WD, Fautsch MP. Stanniocalcin-1 is an ocular hypotensive agent and a downstream effector molecule that is necessary for the intraocular pressure-lowering effects of latanoprost. Invest Ophthalmol Vis Sci. 2017;58:2715–24.
   PubMed Web of Science ®Google Scholar
• Tang SE, Wu CP, Wu SY, Peng CK, Perng WC, Kang BH, Chu SJ, Huang KL. Stanniocalcin-1 ameliorates lipopolysaccharide-induced pulmonary oxidative stress, inflammation, and apoptosis in mice. Free Radic Biol Med. 2014;71(321–331).
   Google Scholar
• Huang L, Belousova T, Pan JS, Du J, Ju H, Lu L, Zhang P, Truong LD, Nuotio-Antar A, Sheikh-Hamad D. Aki after conditional and kidney-specific knockdown of stanniocalcin-1. J Am Soc Nephrol. 2014;25:2303–15.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Ko JH, Yun JH, Kim JA, Kim TE, Lee HJ, Kim SH, Park KH, Oh JY. Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage. PLoS One. 2013;8:e63749.
   PubMed Web of Science ®Google Scholar
• Liu D, Shang H, Liu Y. Stanniocalcin-1 protects a mouse model from renal ischemia-reperfusion injury by affecting ros-mediated multiple signaling pathways. Int J Mol Sci. 2016;17(1051).
   Web of Science ®Google Scholar
• Huang L, Zhang L, Ju H, Li Q, Pan JS, Al-Lawati Z, Sheikh-Hamad D. Stanniocalcin-1 inhibits thrombin-induced signaling and protects from bleomycin-induced lung injury. Sci Rep. 2015;5(18117).
   Google Scholar
• Wu LM, Guo R, Hui L, Ye YG, Xiang JM, Wan CY, Zou M, Ma R, Sun XZ, Yang SJ, et al. Stanniocalcin-1 protects bovine intestinal epithelial cells from oxidative stress-induced damage. J Vet Sci. 2014;15(4):475–83.
   PubMed Web of Science ®Google Scholar
• Shi X, Wang J, Qin Y. Recombinant adeno-associated virus-delivered hypoxia-inducible stanniocalcin-1 expression effectively inhibits hypoxia-induced cell apoptosis in cardiomyocytes. J Cardiovasc Pharmacol. 2014;64:522–29.
   PubMed Web of Science ®Google Scholar
• Roddy GW, Rosa RH Jr., Oh JY, Ylostalo JH, Bartosh TJ Jr., Choi H, Lee RH, Yasumura D, Ahern K, Nielsen G, et al. Stanniocalcin-1 rescued photoreceptor degeneration in two rat models of inherited retinal degeneration. Mol Ther. 2012;20(4):788–97.
   PubMed Web of Science ®Google Scholar
• Huang L, Belousova T, Chen M, DiMattia G, Liu D, Sheikh-Hamad D. Overexpression of stanniocalcin-1 inhibits reactive oxygen species and renal ischemia/reperfusion injury in mice. Kidney Int. 2012;82:867–77.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Chang AC, Reddel RR. Stanniocalcin-1 acts in a negative feedback loop in the prosurvival erk1/2 signaling pathway during oxidative stress. Oncogene. 2009;28:1982–92.
   PubMed Web of Science ®Google Scholar
• Durukan Tolvanen A, Westberg JA, Serlachius M, Chang AC, Reddel RR, Andersson LC, Tatlisumak T. Stanniocalcin 1 is important for poststroke functionality, but dispensable for ischemic tolerance. Neuroscience. 2013;229:49–54.
   PubMed Web of Science ®Google Scholar
• Westberg JA, Serlachius M, Lankila P, Penkowa M, Hidalgo J, Andersson LC. Hypoxic preconditioning induces neuroprotective stanniocalcin-1 in brain via il-6 signaling. Stroke. 2007;38:1025–30.
   PubMed Web of Science ®Google Scholar
• Zhang K, Lindsberg PJ, Tatlisumak T, Kaste M, Olsen HS, Andersson LC. Stanniocalcin: a molecular guard of neurons during cerebral ischemia. Proc Natl Acad Sci U S A. 2000;97:3637–42.
   PubMed Web of Science ®Google Scholar
• Roddy GW, Rinkoski TA, Monson KJ, Chowdhury UR, Fautsch MP. Stanniocalcin-1 (stc-1), a downstream effector molecule in latanoprost signaling, acts independent of the fp receptor for intraocular pressure reduction. PLoS One. 2020;15:e0232591.
   PubMed Web of Science ®Google Scholar
• Patel GC, Phan TN, Maddineni P, Kasetti RB, Millar JC, Clark AF, Zode GS. Dexamethasone-induced ocular hypertension in mice: effects of myocilin and route of administration. Am J Pathol. 2017;187:713–23.
   PubMed Web of Science ®Google Scholar
• Turner AJ, Vander Wall R, Gupta V, Klistorner A, Graham SL. Dba/2j mouse model for experimental glaucoma: pitfalls and problems. Clin Exp Ophthalmol. 2017;45:911–22.
   PubMed Web of Science ®Google Scholar
• John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D, Davisson M, Roderick TH, Heckenlively JR. Essential iris atrophy, pigment dispersion, and glaucoma in dba/2j mice. Invest Ophthalmol Vis Sci. 1998;39:951–62.
   PubMed Web of Science ®Google Scholar
• Denis P, Baudouin C, Bron A, Nordmann JP, Renard JP, Rouland JF, Sellem E, Amrane M. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010;10(4).
   Google Scholar
• Sheldon WG, Warbritton AR, Bucci TJ, Turturro A. Glaucoma in food-restricted and ad libitum-fed dba/2nnia mice. Lab Anim Sci. 1995;45:508–18.
   PubMedGoogle Scholar
• Chang B, Smith RS, Hawes NL, Anderson MG, Zabaleta A, Savinova O, Roderick TH, Heckenlively JR, Davisson MT, John SW. Interacting loci cause severe iris atrophy and glaucoma in dba/2j mice. Nat Genet. 1999;21:405–09.
   PubMed Web of Science ®Google Scholar
• Chen R, Yang K, Zheng Z, Ong ML, Wang NL, Zhan SY. Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma. J Glaucoma. 2016;25:e134–144.
   PubMed Web of Science ®Google Scholar
• Sawada K, Hiraoka M, Ohguro H. Effect of antiglaucoma medicine on intraocular pressure in dba/2j mice. Ophthalmic Res. 2016;55:205–11.
   PubMed Web of Science ®Google Scholar
• Roddy GW, Yasumura D, Matthes MT, Alavi MV, Boye SL, Rosa RH Jr., Fautsch MP, Hauswirth WW, LaVail MM. Long-term photoreceptor rescue in two rodent models of retinitis pigmentosa by adeno-associated virus delivery of stanniocalcin-1. Exp Eye Res. 2017;165(175–181).
   PubMed Web of Science ®Google Scholar